H.C. Wainwright analyst Andres Maldonado initiated coverage of enGene (ENGN) with a Buy rating and $25 price target The firm says the The non-muscle invasive bladder cancer treatment landscape is undergoing a renaissance, and enGene’s detalimogene “represents an innovative treatment option.” Detalimogene’s profile holds several competitive advantages in NMIBC, the analyst tells investors in a research note. The firm believes its expectations of efficacy for detalimogene “remain well within reach.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles
- FedEx to separate Freight unit, Nike reports Q2 beat: Morning Buzz
- enGene reports FY24 EPS ($1.46), consensus ($1.39)
- enGene initiated with an Outperform at Raymond James
- enGene initiated with an Outperform at JMP Securities